Last reviewed · How we verify
VXA-GI.1.NN
At a glance
| Generic name | VXA-GI.1.NN |
|---|---|
| Sponsor | Vaxart |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females and Their Nursing Infants (PHASE1)
- Norovirus Challenge Study (PHASE1, PHASE2)
- A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old (PHASE1)
- A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers (PHASE2)
- A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers (PHASE1)
- Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines (PHASE1, PHASE2)
- Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine (PHASE1)
- Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |